OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacoeconomics is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”	140
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling	123
Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	78
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment	70
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis	64
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment	61
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?	54
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children	52
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy	46
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	44
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy	39
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned	39
Advancing Methods to Measure and Reward Healthcare Innovation	38
Bayesian Meta-Analysis: A Practical Introduction	37
Innovation Headroom for a Highly Accurate PD-L1 Companion Diagnostic in Non-small Cell Lung Cancer	36
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based	36
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation	35
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling	35
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review	34
The Economic Burden of Inflammatory Arthritis: A Systematic Review	32
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States	32
Caring for and Caring about in Economic Evaluation: Modelling the Family and Caregiving Effects	32
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA	31
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review	31
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review	31

Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies	30
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions	28